Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Fig. 2

Characterization of piggyBac-NKG2D.CAR/PBAE 447 vector construct. a Structures of piggyBac transposon/transposase plasmids encoding CAR construct. On the left (N) is the piggyBac donor plasmid encoding the NKG2D-DAP10-CD3ζ CAR gene. On the right (T) is the piggyBac helper plasmid containing the transposase gene. b Agarose gel electrophoresis images of naked plasmid DNA (N and T), transposon/transposase: PBAE 447 complexes (P/N and P/T) (mass ratio of PBAE 447 to N or T is 5, 10, 20, 40, and 80, respectively), and PBAE 447/piggyBac-NKG2D.CAR complexes (P/N/T) (mass ratio of PBAE 447 to total DNAs is 40, and the mass ratio of N to T is 1, 2.5, and 5). c TEM images and DLS mean size of P/N/T complex. Bar = 100 nm. d Zeta potential of P/N/T. In both (c) and (d), the mass ratio of PBAE 447 to total DNA (N and T) is 40, and the mass ratio of N to T varies from 1, 2.5, and 5. Herein, samples are referred as P/D (1:1), P/D (2.5:1), and P/D (5:1), respectively. Data are presented as the mean ± SEM (n = 3)

Back to article page